Navigation Links
United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
Date:2/19/2008

- Total Annual Revenues of $210.9 Million

- Annual EPS of $0.94 per Basic Share, or $0.88 per Diluted Share - Annual EBITDASO of $4.03 per Basic Share, or $3.81 per Diluted Share

SILVER SPRING, Md., Feb. 19 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced financial results for the fourth quarter and year ended December 31, 2007.

"We are pleased to report that United Therapeutics' revenues for the year ended December 31, 2007, totaled $210.9 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "This is the sixth straight year our revenues have grown by more than 30%. Our EBITDASO (earnings before interest, taxes, depreciation, amortization and stock option expense) for the year were $85.5 million, or $4.03 per basic share."

Net income for the three months ended December 31, 2007, was $2.0 million or $0.09 per basic share, as compared to $55.5 million or $2.54 per basic share for the three months ended December 31, 2006. EBITDASO for the three months ended December 31, 2007, was $24.7 million or $1.14 per basic share, as compared to $18.7 million or $0.81 per basic share for the three months ended December 31, 2006. Net income for the year ended December 31, 2007, was $19.9 million or $0.94 per basic share, as compared to $74.0 million or $3.21 per basic share in 2006.

Results

Revenues. Revenues grew to $210.9 million for the year ended December 31, 2007, as compared to $159.6 million for the year ended December 31, 2006, an increase of 32%. Gross margins from sales were $186.5 million, or 89%, in 2007, which is consistent with gross margins from sales of $142.6 million, or 89%, in 2006. The table below summarizes the components of our revenues for the three months and years ended December 31, 2007 and 2006 (dollars in thousands):

Three Months Ended Years Ending

December 31, December 31,

2007 2006 2007 2006

Revenues:

Net product sales $56,899 $44,147 $201,348 $153,448

Service sales 2,172 1,679 7,435 6,184

Distributor fees 827 - 2,160 -

Total revenues $59,898 $45,826 $210,943 $159,632

The increases in revenues resulted primarily from growth in sales of Remodulin.

Operating Expenses. Our operating expenses include research and development expenses, sales and marketing expenses, costs of product sales and cost of service sales.

Research and development expenses consist primarily of salaries and related expenses, costs to acquire pharmaceutical products and product rights for development, and amounts paid to contract research organizations, hospitals and laboratories for the provision of services and materials for drug development and clinical trials. The table below summarizes research and development expenses by major project and non-project components for the three months and year ended December 31, 2007 and 2006 (dollars in thousands):

Three Months Ended Years Ending

December 31, December 31,

2007 2006 2007 2006

Project and non-project:

Cardiovascular $8,570 $11,276 $38,459 $33,005

Cancer 3,189 3,231 13,874 10,462

Infectious disease 278 204 824 753

Stock option 3,671 2,600 12,373 9,240

Other 2,002 1,026 6,809 4,110

R&D expense from issuance of

common stock for license - - 11,013 -

Total research and

development expense $17,710 $18,337 $83,352 $57,570

Selling, general and administrative expenses consist primarily of salaries, travel, office expenses, insurance, professional fees, provision for doubtful accounts receivable, depreciation and amortization. The table below summarizes selling, general and administrative expenses by major categories for the three months and year ended December 31, 2007 and 2006 (dollars in thousands):

Three Months Ended Years Ending

December 31, December 31,

2007 2006 2007 2006

Category:

General and administrative $11,361 $7,300 $34,933 $25,434

Sales and marketing 7,826 4,584 24,159 14,438

Impairment charges 2,068 - 3,582 2,024

Stock option 22,971 7,303 36,353 14,156

Total selling, general

and administrative expense $44,226 $19,187 $99,027 $56,052

For the year ended December 31, 2007, as compared to the year ended December 31, 2006, the increase in general and administrative expenses was primarily related to increased expenses for salaries, associated expenses and other operating expenses from growth in our operations. The increase in sales and marketing related expenses was primarily related to increased salaries and an increase in headcount, marketing, travel and associated expenses from growth in our operations. The trends for the three-month period ended December 31, 2007, as compared to the same period in 2006, are similar to those noted for the annual period.

The impairment charge during the three months ended December 31, 2007, was primarily related to an other-than-temporary decline of our investment in ViRexx Medical Corp. due to the unsuccessful results of our IMPACT I and II Phase III clinical trials of OvaRex in advanced ovarian cancer.

Stock option expense increased during the three-month and twelve-month periods ended December 31, 2007, over the same periods in 2006, primarily as a result of a stock option grant to our Chief Executive Officer based on the 89% increase in our share price during 2007.

Interest Income. Interest income for the year ended December 31, 2007, was $13.6 million, as compared to interest income of $10.7 million for the year ended December 31, 2006. The difference was due primarily to an increase in market interest rates and amounts available to invest. Interest income for the three months ended December 31, 2007, was comparable to interest income for the same period in 2006.

Income Tax Benefit. We recognized an income tax benefit of approximately $3.3 million and $34.1 million for the years ended December 31, 2007 and 2006, respectively. For the three-month periods ended December 31, 2007 and 2006, we recognized a tax benefit of $7.1 million and $47.7 million, respectively. The tax benefit recognized for 2007 was primarily due to the amount of tax credits generated during the year from our orphan drug related research and development activities. For the year ended December 31, 2006, the tax benefit recognized was primarily due to a reduction of approximately $45.7 million in the valuation allowance against most of our deferred tax assets based on our determination that certain portions of these deferred tax assets are more likely than not realizable.

EBITDASO Calculation

The following table provides a reconciliation of net income and EBITDASO for the three-month periods ended December 31, 2007 and 2006, and for the years ended December 31, 2004 through 2007 (in thousands, except per share data):

Year ended December 31,

2004 2005 2006 2007

Net income, as reported $15,449 $65,016 $73,965 $19,859

Add (subtract) back:

Interest expense 4 29 482 2,175

Income tax (benefit) - (17,494) (34,057) (3,276)

One time expense - - 2,024 14,595

Depreciation and

amortization 2,381 2,534 2,713 3,427

Stock option expense 329 983 23,513 48,766

EBITDASO $18,163 $51,068 $68,640 $85,546

EBITDASO earnings per

share (1):

Basic $0.84 $2.24 $2.98 $4.03

Diluted $0.78 $2.03 $2.84 $3.81

Three months ended

December 31,

2007 2006

Net income, as reported $1,986 $55,508

Add (subtract) back:

Interest expense 34 481

Income tax (benefit) (7,104) (47,718)

One time expense 2,067 -

Depreciation and

amortization 941 770

Stock option expense 26,792 9,687

EBITDASO $24,716 $18,728

EBITDASO earnings per

share (1):

Basic $1.14 $0.86

Diluted $1.04 $0.82

(1) Calculated by dividing EBITDASO from above by weighted average shares outstanding, as reported below.

Conference Call

United Therapeutics will host a half-hour teleconference on Tuesday, February 19, 2008, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-800-603-1777, with international callers dialing 1- 706-679-8129. A rebroadcast of the teleconference will be available for one week by dialing 1-800-642-1687, with international callers dialing 1-706-645- 1687, and using access code 33422885.

This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/eventdetail.cfm?eventid=51056.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

Non-GAAP Financial Information

This press release contains certain financial measures that do not comply with GAAP, which measures supplement our financial results prepared in accordance with GAAP.

We use EBITDASO, a non-GAAP measure, for our operating, budgeting and financial planning purposes and as a metric for our Company-wide Milestone Incentive Bonus Program, and believe our investors' understanding of our performance is enhanced by disclosing this measure.

The presentation of these non-GAAP financial measures is not to be considered in isolation or as a substitute for our financial results prepared in accordance with GAAP.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These forward-looking statements include our expectations and intentions regarding the payment of federal and state income taxes for 2007, the generation of taxable income, the availability and utilization of net operating loss carry forwards to reduce taxable income, and the availability, creation and utilization of research tax credits to pay income taxes that are based on our current beliefs and expectations as to future outcomes. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated results. Consequently, such forward- looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Reform Act of 1995 for forward-looking statements. We are providing this information as of February 19, 2008, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Remodulin is a registered trademark of United Therapeutics Corporation.

OvaRex is a registered trademark of AltaRex Medical Corp.

UNITED THERAPEUTICS CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended Years Ending

December 31, December 31,

2007 2006 2007 2006

Revenues:

Net product sales $56,899 $44,147 $201,348 $153,448

Service sales 2,172 1,679 7,435 6,184

Distributor fees 827 - 2,160 -

Total revenues 59,898 45,826 210,943 159,632

Operating expenses:

Research and development 17,710 18,337 83,352 57,570

Selling, general and

administrative 44,226 19,187 99,027 56,052

Cost of product sales 5,745 4,251 19,919 14,973

Cost of service sales 612 502 2,342 2,055

Total operating expenses 68,293 42,277 204,640 130,650

Income (loss) from operations (8,395) 3,549 6,303 28,982

Other income (expense):

Interest income 3,939 3,653 13,602 10,700

Interest expense (34) (481) (2,175) (482)

Equity (loss) in affiliate (56) (93) (321) (491)

Other, net (572) 1,162 (826) 1,199

Total other income, net 3,277 4,241 10,280 10,926

Income (loss) before income tax

benefit (5,118) 7,790 16,583 39,908

Income tax benefit 7,104 47,718 3,276 34,057

Net income $1,986 $55,508 $19,859 $73,965

Net income per common share:

Basic $0.09 $2.54 $0.94 $3.21

Diluted $0.08 $2.42 $0.88 $3.06

Weighted average number of common

shares outstanding:

Basic 21,666 21,893 21,224 23,010

Diluted 23,746 22,894 22,451 24,138

CONSOLIDATED BALANCE SHEET DATA:

As of December 31,

(In thousands)

2007 2006

Cash, cash equivalents and marketable investments $299,287 $264,163

(excluding restricted amounts of $44,195

and $38,988, respectively)

Total assets $587,884 $478,550

Total liabilities $280,346 $273,944

Total stockholders' equity $296,656 $204,606


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. United States Patent Office Grants CryoCors Request for Patent Interference
2. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
3. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
4. Nycomeds Ciclesonide to be Commercialised in the United States by Sepracor
5. Chindexs United Family Hospitals and Clinics and NBC Enter into Healthcare Services Agreement
6. Neptune Technologies receives GRAS notification in the United States
7. Essilor: New Acquisitions in the United States and Brazil
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Medical Services Begins Working With United States Companies for Distribution of Its Products
10. United Therapeutics Reports Third Quarter 2007 Financial Results
11. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists and  ... Experiences SHPG ) ... of children born with rare diseases, as well as the future ... a new initiative designed to positively affect the lives of children ... disease care. --> To mark the company,s founding 30 ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
(Date:2/8/2016)... ... February 08, 2016 , ... Thomas J. Todorow has joined ... President for Corporate Services and the Chief Financial Officer at The Children’s Hospital ... Treasury, Managed Care Contracting, Supply Chain, and Investments. , Prior to joining CHOP ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):